Company updateBusiness Today
India pharma shifts to high-value drugs to cut China dependence
Positive+20
GreyOak summary
India's pharmaceutical industry is accelerating a shift toward high-value medicines and advanced manufacturing to reduce reliance on Chinese APIs. Domestic market growth hit 17.1% in September 2026, driven by demand for diabetes and cancer treatments. Government PLI schemes have attracted significant investments, while companies like Jubilant Ingrevia are expanding domestic capabilities.
What it affects
- HealthcarePositive +20
Industry shifts to high-value drugs and advanced manufacturing.Rolling sentiment Positive +33